18+
Utilize fresh tumor tissue to aid the development of future therapies for brain cancer.
Briefly, a cell immunotherapy consisting of a patient’s autologous glioblastoma tumor cells, called ‘IGV-001’, is being tested in clinical trials. In order to advance clinical and product development of IGV-001, Imvax is seeking access to patient material to test key product parameters in a laboratory setting.
The device used to collect the tissue, the Myriad multifunctional device enabling suction, resection, and collection of tumor tissue (see NICO Myriad Use Manual) is an FDA-approved device that is safe
